Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (lucentis): A two-year study

Ophthalmic Plastic and Reconstructive Surgery

Volumn 28, Issue 2, 2012, Pages 85-89

  Finger, Paul T ^a   Chin, Kimberly J ^a  

^a NEW YORK EYE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MITOMYCIN; RANIBIZUMAB;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CANCER SURGERY; CLINICAL ARTICLE; CONJUNCTIVA SQUAMOUS CELL CARCINOMA; CORNEA SQUAMOUS CELL CARCINOMA; CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ECHOGRAPHY; EPIPHORA; EVISCERATION; EYE BIOPSY; EYE CANCER; EYE IRRITATION; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHOTOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER; SLIT LAMP; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; URINALYSIS; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CONJUNCTIVA; CONJUNCTIVAL NEOPLASMS; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS;

EID: 84860884571     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0b013e3182392f29     Document Type: Article

References (36)

1. Yousef Y, Finger PT. Squamous Carcinoma and Dysplasia of the Conjunctiva and Cornea: An Analysis of 101 Cases. Ophthalmology. In press.
2. Finger PT. "Finger-tip" cryotherapy probes: treatment of squamous and melanocytic conjunctival neoplasia. Br J Ophthalmol 2005; 89:942-5. (Pubitemid 41081399)
3. Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol 1995;39:429-50.
4. Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea 2003;22:687-704. (Pubitemid 37175152)
5. Peksayar G, Soytürk MK, Demiryont M. Long-term results of cryo-therapy on malignant epithelial tumors of the conjunctiva. Am J Ophthalmol 1989;107:337-40. (Pubitemid 19100923)
6. Tunc M, Char DH, Crawford B, Miller T. Intraepithelial and inva-sive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol 1999;83:98-103. (Pubitemid 29106341)
7. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology 2010;117:649-58.
8. Wilson MW, Czechonska G, Finger PT, et al. Chemotherapy for eye cancer. Surv Ophthalmol 2001;45:416-44. (Pubitemid 32239519)
9. Finger PT. Topical mitomycin chemotherapy for malignant con-junctival and corneal neoplasia. Br J Ophthalmol 2006:90:807-9.
10. Frucht-Pery J, Sugar J, Baum J, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experi-ence. Ophthalmology 1997;104:2085-93. (Pubitemid 28053436)
11. Majmudar PA, Epstein RJ. Antimetabolites in ocular surface neo-plasia. Curr Opin Ophthalmol 1998;9:35-9.
12. Karp CL, Galor A, Chhabra S, et al. Subconjunctival/perilesional recombinant interferon a2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 2010;117:2241-6.
13. Schechter BA, Koreishi AF, Karp CL, Feuer W. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. Ophthalmology 2008;115:1291-6.
14. Esquenazi S, Fry CL, Holley E. Treatment of biopsy proved con-junctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol 2005;89:1221. (Pubitemid 41224479)
15. Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000;107:2190-5.
16. Midena E, Angeli CD, Valenti M, et al. Treatment of conjunc-tival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 2000;84:268-72. (Pubitemid 30251681)
17. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M. 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol 2010;4:801-8.
18. Finger PT. Radiation therapy for orbital tumors: concepts, cur-rent use, and ophthalmic radiation side effects. Surv Ophthalmol 2009;54:545-68.
19. Graue GF, Tena LB, Finger PT. Electron beam radiation for con-junctival squamous carcinoma. Ophthal Plast Reconstr Surg 2011;27:277-81.
20. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802. (Pubitemid 46038527)
21. Zaki AA, Fouad H, Emera S, Labib H. Subconjunctival Anti VEGF for Conjunctival Intraepithelial and Invasive Neoplasia. Australian J Bas Appl Sci 2009;3:3186-9.
22. Teng CC, Chin KJ, Finger PT. Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. Br J Ophthalmol 2009;93:837-8.
23. Finger PT, Tran HV, Turbin RE, et al. High-frequency ultra-sonographic evaluation of conjunctival intraepithelial neoplasia and squamous cell carcinoma. Arch Ophthalmol 2003;121: 168-72. (Pubitemid 36184028)
24. Pellé G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothe-lial growth factor inhibitors. Am J Kidney Dis 2011;57:756-9.
25. The AJCC-UICC Ophthalmic Oncology Task Force. Carcinoma of the Conjunctiva. In: Edge SE, Byrd DR, Carducci MA, Compton CA, eds. AJCC Cancer Staging Manual, Seventh Edition. New York, New York: Springer, 2010:531-7.
26. Semenova EA, Milman T, Finger PT, et al. The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia. Am J Ophthalmol 2009;148:772-8.
27. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
28. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid ker-atopathy. Cornea 2009;28:1070-3.
29. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-8.
30. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety pro-file and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-82.
31. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevaci-zumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-9.
32. Galor A, Yoo SH, Piccoli FV, et al. Phase I study of subconjunc-tival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol 2010;149:926-31.
33. Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res 2010;43:134-8.
34. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevaci-zumab on primary pterygium. Cornea 2009;28:468-70.
35. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevaci-zumab injection for corneal neovascularization in recurrent ptery-gium. Curr Eye Res 2008;33:23-8. (Pubitemid 351156952)
36. Mauro J, Foster CS. Pterygia: pathogenesis and the role of sub-conjunctival bevacizumab in treatment. Semin Ophthalmol 2009; 24:130-4.